Dr Garry M. Walsh, Reader in Immunity and Inflammation and Principal Investigator, Asthmatic and Allergic Inflammation Group, School of Medicine, Institute of Medical Sciences, University of Aberdeen, Aberdeen, U.K.

Dr Walsh’s research career spans 25 years during which his work has focused on the elucidation of the molecular mechanisms controlling the initiation and resolution of the inflammatory processes underlying asthma, COPD and allergic disease with an emphasis on the role played by airway epithelial cells and eosinophils. Dr Walsh has published in both basic and clinical science, including several seminal papers on cell death, apoptotic cell disposal and the clinical relevance of apoptotic cell clearance.

He has secured over £2 million in research funding as principal investigator from Research Charities including the Wellcome Trust, the Medical Research Council and industry. Dr Walsh has published more than 55 peer reviewed articles and over 50 editorials, reviews and book chapters; these have been cited over 2000 times. He has been an invited speaker and/or chairman at more than 30 prestigious international meetings. Dr Walsh is founding Editor-in-Chief of Therapeutics & Clinical Risk Management and serves as editorial board member for seven international peer-reviewed journals.   He is a regular reviewer for over thirty other journals and is a member of many professional organizations and committees, including the Collegium Internationale Allergologicum.  Dr Walsh is Visiting Professor of Immunity and inflammation in the Department of Clinical Medicine at Trinity College, Dublin, Ireland